浙江眾成(002522.SZ):擬變更部分募集資金用途 新增募投項目“年產3萬噸新型聚烯烴熱收縮膜生產線”
格隆匯 3 月 2日丨浙江眾成(002522.SZ)公佈,公司於2021年3月1日召開第五屆董事會第一次會議和第五屆監事會第一次會議,分別審議通過了《關於變更部分募集資金用途暨新增募投項目的議案》。同意變更公司部分首次公開發行股票募集資金用途,對超募資金項目“年產3000噸高阻隔PVDC熱收縮膜及3000噸EVOH阻隔熱收縮膜建設項目”(“原募投項目”或“該項目”)取消使用首發超募資金建設實施,並使用變更後剩餘的超募資金及自籌資金新設募投項目“年產3萬噸新型聚烯烴熱收縮膜生產線”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.